A tricarbonyl rhenium(I) complex decorated with boron dipyrromethene for endoplasmic reticulum-targeted photodynamic therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence and Fluorescent Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. Photodynamic therapy in dermatology: state-of-the-art10.1111/j.1600-0781.2010.00507.x ↗
2. Photodynamic therapy for infections: clinical applications10.1002/lsm.21080 ↗
3. Photodynamic therapy for cancer10.1038/nrc1071 ↗
4. Photodynamic therapy of cancer: an update
5. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
6. Photodynamic therapy - mechanisms, photosensitizers and combinations10.1016/j.biopha.2018.07.049 ↗
7. Photodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer10.1021/jacs.6b09538 ↗
8. Bioinspired hybrid protein oxygen nanocarrier amplified photodynamic therapy for eliciting anti-tumor immunity and abscopal effect10.1021/acsnano.8b04371 ↗
9. Photodynamic therapy and immunity: an update10.1111/php.13253 ↗
10. Aggregation-induced emission (AIE) dots: emerging theranostic nanolights10.1021/acs.accounts.8b00060 ↗
11. Photosensitizers for photodynamic therapy10.1002/adhm.201900132 ↗
12. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy10.1016/j.apsb.2017.09.003 ↗
13. Boosting cancer therapy with organelle-targeted nanomaterials10.1021/acsami.9b01370 ↗
14. Organelle-targeted photosensitizers for precision photodynamic therapy10.1021/acsami.1c02019 ↗
15. A nuclear targeted dual-photosensitizer for drug-resistant cancer therapy with NIR activated multiple ROS10.1039/C6SC00737F ↗
16. Nucleus-targeted organoiridium-albumin conjugate for photodynamic cancer therapy10.1002/anie.201813002 ↗
17. Pd@Au bimetallic nanoplates decorated mesoporous MnO2 for synergistic nucleus-targeted NIR-II photothermal and hypoxia-relieved photodynamic therapy10.1002/adhm.201901528 ↗
18. Mitochondria-targeted smart AIEgens: imaging and therapeutics10.1016/j.ccr.2022.214818 ↗
19. Cyclometalated iridium(iii) complexes for mitochondria-targeted combined chemo-photodynamic therapy10.1039/D0DT00180E ↗
20. Cancer-cell-activated in situ synthesis of mitochondria-targeting AIE photosensitizer for precise photodynamic therapy10.1002/anie.202017350 ↗
21. Cyclometalated iridium(III) complexes as lysosome-targeted photodynamic anticancer and real-time tracking agents10.1039/C5SC01955A ↗
22. A lysosome-localized thionaphthalimide as a potential heavy-atom-free photosensitizer for selective photodynamic therapy10.1016/j.dyepig.2020.108265 ↗
23. Red-light-responsive Ru complex photosensitizer for lysosome localization photodynamic therapy10.1021/acsami.0c22551 ↗
24. Facile synthesis of AIEgens with wide color tunability for cellular imaging and therapy10.1039/C8SC05805A ↗
25. BODIPYs revealing lipid droplets as valuable targets for photodynamic theragnosis10.1039/C9CC09397D ↗
26. Lipophilic neutral iridium(III) complexes for phosphorescence imaging of lipid droplets and potential photodynamic therapy10.1016/j.dyepig.2022.110387 ↗
27. Endoplasmic reticulum-localized iridium(III) complexes as efficient photodynamic therapy agents via protein modifications10.1021/jacs.6b05302 ↗
28. Endoplasmic reticulum-localized two-photon-absorbing boron dipyrromethenes as advanced photosensitizers for photodynamic therapy10.1021/acs.jmedchem.7b01907 ↗
29. Enhancing the ROS generation ability of a rhodamine-decorated iridium(iii) complex by ligand regulation for endoplasmic reticulum-targeted photodynamic therapy10.1039/D0SC04751A ↗
30. The endoplasmic reticulum: structure, function and response to cellular signaling10.1007/s00018-015-2052-6 ↗
31. Integrated endoplasmic reticulum stress responses in cancer10.1158/0008-5472.CAN-07-1705 ↗
32. Enzymatic assemblies disrupt the membrane and target endoplasmic reticulum for selective cancer cell death10.1021/jacs.8b04641 ↗
33. Triplet photosensitizers: from molecular design to applications10.1039/c3cs35531d ↗
34. Engineering of relevant photodynamic processes through structural modifications of metallotetrapyrrolic photosensitizers10.1016/j.ccr.2016.06.007 ↗
35. Critical overview of the use of Ru(II) polypyridyl complexes as photosensitizers in one-photon and two-photon photodynamic therapy10.1021/acs.accounts.7b00180 ↗
36. Dual function luminescent transition metal complexes for cancer theranostics: the combination of diagnosis and therapy10.1016/j.ccr.2018.11.013 ↗
37. Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy10.1016/j.ccr.2018.03.020 ↗
38. New designs for phototherapeutic transition metal complexes10.1002/anie.201905171 ↗
39. Recent advances in ruthenium(II) and iridium(III) complexes containing nanosystems for cancer treatment and bioimaging10.1016/j.ccr.2021.214016 ↗
40. Luminescent and photofunctional transition metal complexes: from molecular design to diagnostic and therapeutic applications10.1021/jacs.2c03437 ↗
41. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD143310.1021/acs.chemrev.8b00211 ↗
42. Underestimated potential of organometallic rhenium complexes as anticancer agents10.1021/cb500528c ↗
43. Mitochondrial localization of highly fluorescent and photostable BODIPY-based ruthenium(II), rhodium(III), and iridium(III) metal complexes10.1021/acs.inorgchem.9b00898 ↗
44. BODIPY-Ruthenium(II) bis-terpyridine complexes for cellular imaging and type-I/-II photodynamic therapy10.1021/acs.inorgchem.1c01850 ↗
45. Lysosome targeting bis-terpyridine ruthenium(II) complexes: photophysical properties and in vitro photodynamic therapy10.1021/acsabm.0c00647 ↗
46. BODIPY-based probes for the fluorescence imaging of biomolecules in living cells10.1039/C5CS00030K ↗
47. Photosensitization and controlled photosensitization with BODIPY dyes10.1016/j.ccr.2017.09.029 ↗
48. Application of multifunctional BODIPY in photodynamic therapy10.1016/j.dyepig.2020.108937 ↗
49. BODIPY photosensitizers based on PET and heavy atom effect: a comparative study on the efficient formation of excited triplet state and singlet oxygen in BODIPY dimers and monomers10.1016/j.jphotochem.2017.07.019 ↗
50. Fine-tuning the electronic structure of heavy-atom-free BODIPY photosensitizers for fluorescence imaging and mitochondria-targeted photodynamic therapy10.1039/D0SC01171A ↗
51. Release of CO and production of O-1(2) from a Mn-BODIPY photoactivated CO releasing molecule with visible light10.1021/acs.organomet.1c00331 ↗
52. Rational design of a lysosome-targeting and near-infrared absorbing Ru(ii)-BODIPY conjugate for photodynamic therapy10.1039/D0CC06926D ↗
53. Ruthenium(II) conjugates of boron-dipyrromethene and biotin for targeted photodynamic therapy in red light10.1021/acs.inorgchem.9b03178 ↗
54. Novel ruthenium(II) and iridium(III) BODIPY dyes: insights into their application in photodynamic therapy in vitro10.1039/c9pp00201d ↗
55. Real-time tracking of ER turnover during ERLAD by a rhenium complex via lifetime imaging10.1093/nsr/nwab194 ↗
56. A boron dipyrromethene (BODIPY)-Based Cu-II-Bipyridine complex for highly selective NO detection10.1002/chem.201502191 ↗
57. Rhenium bipyridine complexes for the recognition of glucose10.1021/ic010202b ↗
58. Targeted reversal and phosphorescence lifetime imaging of cancer cell metabolism via a theranostic rhenium(I)-DCA conjugate10.1016/j.biomaterials.2018.05.040 ↗
59. Recoding the cancer epigenome by intervening in metabolism and iron homeostasis with mitochondria-targeted rhenium(I) complexes10.1002/anie.202008624 ↗
60. Impairment of the autophagy-related lysosomal degradation pathway by an anticancer rhenium(i) complex10.1039/C9DT00322C ↗
61. A mitochondria-targeted iridium(iii)-based photoacid generator induces dual-mode photodynamic damage within cancer cells10.1039/C9CC04871E ↗
62. A compilation of singlet oxygen yields from biologically relevant molecules10.1111/j.1751-1097.1999.tb08240.x ↗
63. Dinuclear phosphorescent rhenium(I) complexes as potential anticancer and photodynamic therapy agents10.1039/D0DT02424D ↗
64. Standards for photoluminescence quantum yield measurements in solution
65. Cyclometalated iridium-BODIPY ratiometric O2 sensors10.1039/C9SC00696F ↗
66. Oncologic photodynamic therapy: basic principles, current clinical status and future directions10.3390/cancers9020019 ↗
67. Cytotoxic BODIPY-appended half-sandwich iridium(III) complex forms protein adducts and induces ER stress10.1021/acs.jmedchem.1c01335 ↗
68. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress10.1021/tx00026a012 ↗
69. Quenching of singlet molecular oxygen (1O2) by azide anion in solvent mixtures10.1562/0031-8655(2001)074<0760:QOSMOO>2.0.CO;2 ↗
70. β-Elemonic acid inhibits the growth of human Osteosarcoma through endoplasmic reticulum (ER) stress-mediated PERK/eIF2α/ATF4/CHOP activation and Wnt/β-catenin signal suppression10.1016/j.phymed.2020.153183 ↗
71. Endoplasmic reticulum-mitochondria contacts: function of the junction10.1038/nrm3440 ↗
72. Apoptosis: controlled demolition at the cellular level10.1038/nrm2312 ↗